Navigation Links
Published Study Shows VNUS ClosureFAST™ System Significantly Superior to Laser for Varicose Vein Treatment
Date:6/10/2009

Journal of Vascular & Interventional Radiology Cites Improved Recovery and Quality-of-Life with VNUS Technology

San Jose, CA (PRWEB) June 10, 2009 -- VNUS® Medical Technologies, Inc. (NASDAQ: VNUS), a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, announced today that the Journal of Vascular & Interventional Radiology, the prestigious monthly publication of the Society of Interventional Radiology, has published a study showing the VNUS ClosureFAST™ system for radiofrequency (RF) thermal ablation to be "significantly superior" to endovenous laser (EVL) for treating venous reflux, the underlying cause of symptomatic varicose veins.

The VNUS ClosureFAST catheter is a minimally invasive device generally used in the physician's office with a local anesthetic to heat and seal the great saphenous vein, the most common site of venous reflux in the leg. The RECOVERY trial was a multicenter, randomized, single-blinded study of 87 vein ablation procedures in 69 patients, comparing the ClosureFAST radiofrequency catheter to the 980 nm endovenous laser system. The study found that for all primary endpoints in the trial, the ClosureFAST radiofrequency catheter was statistically superior to laser treatment in providing a fast and comfortable recovery for the patient after treatment. Specifically, radiofrequency vein ablation using the ClosureFAST catheter was shown to result in less postoperative pain, less bruising, less tenderness, and better reduction of symptoms than laser as soon as two days after treatment, and remaining considerably better for at least two weeks or longer. In addition, all statistical differences in post procedural and quality-of-life parameters were superior in the ClosureFAST group, and minor complications were five times less prevalent.

"The study found RF thermal ablation, as performed with the ClosureFAST catheter, superior to EVL as measured by a comprehensive array of postprocedural recovery and QOL comparisons between these two minimally invasive techniques for closure of the greater saphenous vein," said Jose I. Almeida, M.D., lead author of the study and Medical Director of Miami Vein Center.

"The study confirms what many of us who have used both laser and radiofrequency devices have felt subjectively - that there is significantly enhanced patient comfort with the radiofrequency technology," said Raymond G. Makhoul, M.D., of Richmond, Virginia, a researcher for the study. "The ClosureFAST device clearly provided a superior patient experience."

"This study emphatically supports the experience of our customers who frequently describe the ease of use of our ClosureFAST radiofrequency catheter and the rapid and mild recovery of patients treated with the catheter," said Brian E. Farley, President and CEO of VNUS. "The trial data also explains the enthusiastic adoption of our technology by the physician community. The publication of the RECOVERY Trial results complements other medical journal publications showing over 97% efficacy from the ClosureFAST catheter. Together with the positive endorsement from European national health authorities, we believe this therapy can be regarded as the premier technology for the treatment of venous reflux disease, a medical condition afflicting millions of people worldwide."

ABOUT VNUS MEDICAL TECHNOLOGIES, INC.
Founded in 1995 and headquartered in San Jose, California, VNUS Medical Technologies (NASDAQ: VNUS) is a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition that is the underlying cause of varicose veins. VNUS sells the Closure system, which consists of a proprietary radiofrequency (RF) generator and proprietary disposable endovenous catheters and devices to treat diseased veins through the application of temperature-controlled RF energy. For more information, please visit www.vnus.com.

###

Read the full story at http://www.prweb.com/releases/VNUS-Medical-Technologies/ClosureFAST/prweb2508434.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Two studies published in the Lancet
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. New report on mobile phone research published
5. 2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available
6. Meta-Analysis of Blood Phe Levels and Clinical Outcomes in PKU Published
7. Clinical Study Published Showing Benefits of Glue Used in Facelift Surgery
8. New tool to assess excessive daytime sleepiness in adolescents published in JCSM
9. Published Results Using AtriCure Minimally Invasive Products
10. Mirixa Debuts RxFYI - a Free Pharmacy-Published Health eNewsletter Building Patient Loyalty and Generating Revenue
11. Long Term Care Newsletter Debuts, Published by LTC Financial Partners; Advice on Living Better, Not Just Longer, With Financial Protection
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Published Study Shows VNUS ClosureFAST™ System Significantly Superior to Laser for Varicose Vein Treatment
(Date:2/24/2017)... Charlevoix, MI (PRWEB) , ... February 24, 2017 ... ... venue in Charlevoix, once again hosted their Military Wedding Giveaway, with the ... be hosted by Castle Farms with services generously donated from local vendors: A ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased ... KLS is a longtime supporter of the event. , "We are pleased that KLS ... Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record of ...
(Date:2/23/2017)... Hollywood, CA (PRWEB) , ... February 23, 2017 , ... ... pleased to announce that they are sponsoring a raffle. Throughout the month of February, ... Winners will receive a gift card for a dinner for two at the Cheesecake ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Feb. 24, 2017 Juan Monteverde , ... PC , a boutique securities firm headquartered at the ... , announces that a class action lawsuit has ...  against Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or ... securities between July 23, 2015 and December 30, 2016, inclusive ...
(Date:2/24/2017)... -- Directors from Pharma To Market Pty Ltd and Ador Consulting Pte ... the founding of Pharma To Market Pte Ltd, based in ... to announce their expansion into Asia with ... The company are delighted to appoint Joelle Chia , former ... based entity. Joelle brings with her an extensive business ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an ... that it has acquired exclusive worldwide rights to ... innovative HDAC inhibitor targeting hematological and solid tumors. ... Phase 1 and 2 clinical trials of Abexinostat ... have already been completed, demonstrating that Abexinostat ...
Breaking Medicine Technology: